Frank Bergman
In a groundbreaking development for cancer treatment, scientists have announced that ivermectin may offer new hope in the battle against chemotherapy-resistant ovarian cancer.
Ivermectin, most commonly known as an antiparasitic, has been emerging as a major new treatment in fighting multiple forms of cancer.
The study was led by Dr. Cláudia Santos and conducted by researchers from UCIBIO and CESPU.
The findings were published in the medical journal Scientific Letters.
The study reveals that ivermectin may play a key role in overcoming chemotherapy resistance by targeting a critical protein marker, ALDH1.
ALDH1 has been linked to poor treatment responses and tumor relapse.
The research demonstrates that when ivermectin was combined with chemotherapy agents carboplatin and paclitaxel, ovarian cancer cells showed a dramatic decrease in ALDH1 expression.
The scientists note that this is a key factor in chemotherapy resistance.
The results were obtained from both standard and paclitaxel-resistant ovarian cancer cell lines and under different growth conditions, including 2D and 3D cell cultures.
The combination therapy significantly outperformed treatments using chemotherapy alone.
The findings provide a promising avenue to enhance the effectiveness of existing cancer therapies.
This breakthrough is crucial because ovarian cancer remains one of the deadliest cancers.
It has a high rate of relapse due to chemoresistance.
The use of ivermectin, a widely available and cost-effective drug, could potentially reverse this resistance.
It offers a groundbreaking new strategy for improving patient outcomes.
The research team is now calling for clinical trials to further explore ivermectin’s role as an adjunct treatment for ovarian cancer.
The scientists are hoping it could open the door to repurposing affordable medications to combat some of the most challenging cancers.
With the increasing interest in drug repurposing for hard-to-treat cancers, this study provides a compelling reason to investigate ivermectin’s potential.
The drug, already approved and used worldwide, could become a critical tool in cancer treatment.
The use of the drug could make a real difference for patients who face limited options.
The growing body of evidence suggests that ivermectin’s role in overcoming chemotherapy resistance is worth exploring on a larger scale.
Its inclusion in cancer therapies could be a game-changer for the medical community.
This is a major step forward in cancer treatment and another example of how repurposing existing drugs could provide solutions to some of the most pressing medical challenges.
Repurposing drugs means they can be used quickly, without the need for years of development.
For many cancer sufferers around the world, the findings could offer some fresh hope.
And many other cancers even without the chemo drugs.
Yes Curious. Their trials do not seem to have Invermectin on it’s own –ie it could be it is doing all the heavy lifting and the chemo is not doing much at all.
Yup, the much maligned “Horse Paste” . Still taking it, still to experience a side effect ( other than good health).
And third place in the Auckland Cup. 🙂
Only because I like galloping behind the fillies in front….
end up with adern gnashers !!
eek
won by a tooth …
Call shonkey. He pulls pony tails.